Login to Your Account



Dievini Hopp Shows Mettle for EU Biotech Investing

By Cormac Sheridan
Staff Writer

Tuesday, September 18, 2012
The €80 million (US$104.9 million) investment by dievini Hopp BioTech Holding GmbH & Co. KG in Tuebingen, Germany-based CureVac GmbH is not only its single biggest bet to date, but also a clear point of differentiation between itself and most other private investors in European biotechnology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription